Oncopeptides AB (publ), a biotech company, engages in the commercialization, and research and development of treatments for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is melflufen, a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden
Stock data | 2024 | Change |
---|---|---|
Price | $0.19494944915446344 | N/A |
Market Cap | $17.63M | N/A |
Shares Outstanding | 90.44M | N/A |
Employees | 64.00 | N/A |